促生长疗法的有效性。生长激素、可乐定和左旋多巴之间的比较。

Effectiveness of growth-promoting therapies. Comparison among growth hormone, clonidine, and levodopa.

作者信息

Volta C, Ghizzoni L, Muto G, Spaggiari R, Virdis R, Bernasconi S

机构信息

Department of Pediatrics, University of Parma, Italy.

出版信息

Am J Dis Child. 1991 Feb;145(2):168-71. doi: 10.1001/archpedi.1991.02160020060017.

DOI:10.1001/archpedi.1991.02160020060017

PMID:1994682

Abstract

The ability of growth hormone, clonidine, and levodopa to stimulate growth was compared in short and slowly growing children randomly assigned to different treatment regimens for 6 months. There were 10 children in each group, and 10 additional subjects served as controls. Growth hormone improved mean height velocity, height velocity SD score, and height SD score. The mean height velocity and height velocity SD score were significantly increased by clonidine, while levodopa only enhanced the mean height velocity SD score of the treated children. Moreover, in nine patients (90%) receiving growth hormone, two (20%) receiving clonidine, and one (10%) receiving levodopa, the height velocity was raised by more than 2 cm/y. The increments in height velocity and height SD score were greatest in the growth hormone group. Clonidine induced an increase in height velocity significantly different from that in control children only. In the control group, there was a significant reduction of height SD score with time.

摘要

对生长激素、可乐定和左旋多巴刺激生长的能力进行了比较，研究对象为随机分配到不同治疗方案下、为期6个月的身材矮小且生长缓慢的儿童。每组有10名儿童，另有10名受试者作为对照。生长激素改善了平均身高增长速度、身高增长速度标准差评分和身高标准差评分。可乐定显著提高了平均身高增长速度和身高增长速度标准差评分，而左旋多巴仅提高了接受治疗儿童的平均身高增长速度标准差评分。此外，在接受生长激素治疗的9名患者（90%）、接受可乐定治疗的2名患者（20%）和接受左旋多巴治疗的1名患者（10%）中，身高增长速度提高了超过2厘米/年。身高增长速度和身高标准差评分的增幅在生长激素组中最大。可乐定引起的身高增长速度增加仅与对照儿童有显著差异。在对照组中，身高标准差评分随时间显著降低。